Thanks for Nodus-ing: Basilea hands off preclinical oncology program for $248M in ongoing anti-infectives pivot
Looks like Basilea Pharmaceutica is getting closer to its final days as an oncology company.
The Switzerland-based Roche offshoot said Thursday that it had sold the company’s preclinical PARG checkpoint inhibitor program to UK-based Nodus Oncology. PARG, or poly(ADP-ribose) glycohydrolase, is an enzyme used to repair DNA damage and had been investigated as a potential oncology target. Nodus will be partnering with German research institute Lead Discovery Center GmbH to continue development of the program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.